NR3C1 and breast cancer: We hypothesize that GR antagonism will enhance chemotherapy sensitivity of GR+/ER− breast cancer cells by blocking stress-mediated cell survival pathways that would otherwise counteract chemotherapy-induced apoptosis in tumor cells.